Healwell AI Reaches Profitability Milestone as Strategic Sale and xAI Stake Fuel Turnaround Hopes

Healwell AI reports first positive adjusted EBITDA after pivoting to software/AI, with revenue up 316%. Stock down 40% YTD, but analysts see upside from xAI stake and U.S. expansion.

A leaner, software-focused Healwell AI has posted its first positive adjusted EBITDA, yet the stock continues to languish near multi-year lows. Shares closed at €0.53 on Friday, down 1.48% on the day and roughly 40% lower than where they started the year — a stark contrast to the operational progress the company has been reporting.

The health-tech firm, which has divested its clinical research and patient services arms, now operates as a pure-play software and artificial intelligence provider. That structural overhaul is starting to show up in the numbers. For the first quarter of fiscal 2026, revenue from continuing operations surged 316% year-over-year to C$33.2 million, largely thanks to the acquisition of Orion Health. The artificial intelligence and data science segment grew 13% to C$2.6 million, while adjusted EBITDA swung to positive C$0.7 million from a loss of over C$1 million a year earlier. The net IFRS loss narrowed to C$6.8 million, almost halving from the prior-year period.

Cash, a xAI Wild Card, and a Pending Divestiture

Healwell ended the quarter with C$21.9 million in cash, providing a comfortable cushion for the next phase of its expansion. But a potentially game-changing asset sits off the balance sheet: the company holds a strategic stake in xAI, the artificial intelligence venture tied to the SpaceX ecosystem. Management has indicated the position represents "significant value" beyond the reported cash reserves, and monetising it could accelerate U.S. market initiatives.

More immediately, the company is racing to complete the sale of its subsidiary HEAL Access Canada to AI Maverick Intel by the end of May. The deal involves 20 million exchange shares and a secured seller note worth US$5 million, contingent on the buyer maintaining positive net working capital of the same amount. If closed, the transaction would further sharpen Healwell’s focus on software and AI.

Analysts Divided on Valuation, Upbeat on Upside

Despite the operational uptick, analysts have been trimming their expectations. TD Securities, Raymond James, Stifel and Scotiabank recently lowered their average price target to C$3.10, citing modestly adjusted margin assumptions and lower valuation multiples. The broader consensus, however, sits at C$2.48, reflecting the ongoing integration of recent acquisitions. Both figures imply substantial upside from the current share price.

The company is banking on a U.S. push to close that valuation gap. After landing a multi-million-dollar software contract with an American health network, Healwell is gearing up for further enterprise implementations across North America. The launch of its Amadeus AI platform is slated for the first half of fiscal 2026. Scientific validation continues to build: the DARWEN AI system is now backed by 47 peer-reviewed publications.

Year-End Targets and a Key Shareholder Meeting

Management has set clear financial goals for the remainder of the year: a roughly 50% increase in AI-related revenue and an adjusted EBITDA margin of 10%. The next formal checkpoint for shareholders comes on June 25, 2026, when the annual general meeting will vote on the composition of the board of directors.

For now, the market remains sceptical, but the combination of a positive EBITDA milestone, a pending asset sale, and a hidden xAI stake gives Healwell multiple levers to pull as it seeks to convince investors that the turnaround is real.